BG
HBIO icon

Bollard Group’s Harvard Bioscience HBIO Stock Holding History

Bollard Group’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,649
Closed -$289K – 336
2022
Q1 		$289K Hold
4,649
– – 0.01% 201
2021
Q4 		$328K Hold
4,649
– – 0.01% 198
2021
Q3 		$324K Hold
4,649
– – 0.01% 191
2021
Q2 		$387K Hold
4,649
– – 0.01% 176
2021
Q1 		$254K Hold
4,649
– – 0.01% 197
2020
Q4 		$199K Hold
4,649
– – 0.01% 207
2020
Q3 		$140K Hold
4,649
– – 0.01% 223
2020
Q2 		$144K Buy
+4,649
New +$125K 0.01% 215

Other funds holding HBIO

HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bollard Group's HBIO Position: Q2 2022 in Review

Bollard Group sold out of Harvard Bioscience (HBIO) in Q2 2022, closing a stake of 4,649 shares — an estimated $289K sold.

Bollard Group first reported a position in HBIO in Q2 2020 and held it in 8 quarters. The position peaked at $387K in Q2 2021. 90 funds tracked by Wall St. Rank hold HBIO as of Q2 2022.

  • Bollard Group reported no remaining Harvard Bioscience position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 4,649 Harvard Bioscience shares in Q2 2022, an estimated $289K.
  • Bollard Group first reported a position in Harvard Bioscience in Q2 2020 and held it in 8 quarters.
  • Bollard Group's Harvard Bioscience position peaked at $387K in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.